ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,06965
-0,04%
Bitcoin
63.265,49
-0,74%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cytek Biosciences Inc (CTKB)

  7. Cytek Biosciences Inc (CTKB) News

CTKB Cytek Biosciences Inc

5,76
0,13 (2,31%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Cytek Biosciences Inc CTKB NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,13 2,31% 5,76 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
5,69 5,59 5,76 5,76 5,63
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
19.3.202413:00GLOBECytek® Biosciences Names William McCombe Chief Financial..
09.3.202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.3.202400:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.3.202400:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.3.202400:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.3.202400:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202423:30GLOBECytek® Biosciences Opens New Facility to Address Increasing..
01.3.202412:06EDGAR2Form 8-K - Current report
28.2.202423:05GLOBECytek Biosciences Reports Fourth Quarter and Full Year 2023..
27.2.202412:06EDGAR2Form 8-K - Current report
22.2.202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202423:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202423:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:07EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07.2.202422:10GLOBECytek Biosciences to Participate in Upcoming Investor..
07.2.202422:05GLOBECytek Biosciences to Report Fourth Quarter and Full Year..
17.1.202423:30GLOBECytek® Biosciences Signs Agreement with CRG and UPF to..
09.1.202412:05EDGAR2Form 8-K - Current report
08.1.202415:00GLOBECytek Biosciences Announces Preliminary Full Year 2023..
28.12.202322:05GLOBECytek Biosciences to present at the 42nd Annual J.P. Morgan..
27.12.202323:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.12.202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.12.202315:00GLOBECytek® Biosciences Introduces the Cytek Orion™ Reagent..
19.12.202322:28EDGAR2Form 144 - Report of proposed sale of securities
28.11.202313:00EDGAR2Form 8-K - Current report
28.11.202302:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.11.202302:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202323:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202323:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202323:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202323:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202323:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.11.202322:17EDGAR2Form 144 - Report of proposed sale of securities
14.11.202322:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.11.202322:05GLOBECytek Biosciences to participate in the Piper Sandler 35th..
13.11.202322:02EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
09.11.202312:06EDGAR2Form 8-K - Current report
09.11.202300:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.11.202315:00GLOBECytek® Aurora™ CS System Wins BioTech Breakthrough Award for..
07.11.202322:45EDGAR2Form 8-K - Current report
07.11.202322:05GLOBECytek Biosciences Reports Third Quarter 2023 Financial..
26.10.202300:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202322:03EDGAR2Form 144 - Report of proposed sale of securities
24.10.202302:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.10.202322:05GLOBECytek Biosciences to Report Third Quarter 2023 Financial..
19.10.202322:02EDGAR2Form 144 - Report of proposed sale of securities

Kürzlich von Ihnen besucht

NASDAQ
CTKB
Cytek Biosciences
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten